Information Provided By:
Fly News Breaks for January 15, 2020
MGTA
Jan 15, 2020 | 08:54 EDT
BTIG analyst Amanda Murphy keeps her Buy rating and $20 price target on Magenta Therapeutics, noting that the 11% sell-off on Monday after the company's press release highlighting its recent milestones and outlining its goals for 2020 was not warranted. The analyst remains positive on Magenta's MGTA-117 conditioning program and sees potential upside from its MGTA-145 data readouts, with expected additional data from the Phase 1 study and the advancement of the product into multiple Phase 2 studies anticipated in 2020.
News For MGTA From the Last 2 Days
There are no results for your query MGTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.